VeloClub is CyclingTips’ membership program which brings us closer to our members, and connects likeminded cycling enthusiasts.
by Neal Rogers
July 1, 2017
In today’s Daily News Digest: Boels-Dolmans wins opening team time trial at Giro Rosa; Cycling Anti-Doping Foundation announces anti-doping measures for Tour de France; Quintana: ‘The biggest rival is still Chris Froome’; Cavendish: ‘Sometimes following the right wheel is enough for winning’; Dan Martin: ‘I’m very optimistic about my chances’; Froome extends with Team Sky through 2020; Fuglsang extends with Astana through 2019; Bardet, Latour, Naesen extend with Ag2r La Mondiale through 2020; Trek, Specialized launch new road framesets on eve of Tour de France; Coryn Rivera extends with Team Sunweb through 2021; Wiggins hopes to compete in rowing at 2020 Olympics; Lance Armstrong launches daily Tour de France podcast.
The Agence Française de Lutte contre le Dopage (AFLD) and the Cycling Anti-Doping Foundation (CADF), the independent body mandated by the Union Cycliste Internationale (UCI) to define and carry out the fight against doping in cycling, confirmed Friday that they will continue their close collaboration on anti-doping controls during the 2017 Tour De France.
The agreement covering the Tour de France is part of the cooperation agreement between the UCI, represented by the CADF, and the AFLD on the other, which aims to ensure efficient anti-doping controls at all the major cycling competitions in France.
Regarding anti-doping controls for the Tour, a comprehensive approach will include targeted controls at the start of the race – in particular through data exchange regarding the whereabouts of the riders – as well as sharing of information concerning the Athlete Biological Passport (ABP), the individual electronic file for each rider that contains results of all anti-doping tests carried out as part of this programme over a certain period.
The AFLD has again carried out controls this year on a number of cyclists who will most likely participate in the race. Shortly before the start of the race, blood checks have been carried out on all participants. During the stages in France, the decision regarding which cyclists to test will be jointly made by the CADF and the AFLD, on the basis of shared information, in order to have a well-targeted approach towards the riders. Based on intelligence gathering, some samples will be kept up to 10 years, in order to allow subsequent analyses with the benefit of technical progress concerning detection methods.
“Our overall testing strategy in 2017 is more than ever based on information gathered through intelligence,” said Francesca Rossi, director of CADF. “The Tour de France does not represent an exception and in this specific event, the CADF can count on the support of the AFLD for information exchange to design the day-to-day testing plan. During the stages in Germany, we will also count on the support of our colleagues from the German Anti-Doping Organisation (NADA).”